icon
icon
Overview

Bile duct cancer, or cholangiocarcinoma, develops when cells lining the bile ducts grow abnormally and form a malignant tumour. The bile ducts carry bile from the liver and gallbladder to the small intestine, where it helps digest fats.

At Apollo Cancer Centres, cholangiocarcinoma care is planned by a multidisciplinary team that may include hepatobiliary and pancreatic surgeons, liver transplant specialists, medical oncologists, radiation oncologists, gastroenterologists, interventional radiologists, radiologists, nuclear medicine specialists, pathologists, genetic specialists, dietitians, and supportive care professionals.

Risk Factors for Cholangiocarcinoma

The exact cause of most bile-duct cancers is unknown. Factors associated with an increased risk may include:
Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis

This chronic inflammatory disease causes scarring and narrowing of the bile ducts and is an important risk factor.
Chronic Bile Duct Inflammation

Chronic Bile Duct Inflammation

Repeated inflammation or obstruction can damage the bile-duct lining over time.
Bile Duct Cysts

Bile Duct Cysts

Choledochal cysts and Caroli disease can increase the risk of cancer.
Hepatolithiasis

Hepatolithiasis

Stones within the bile ducts inside the liver can cause chronic inflammation and increase risk.
Liver-Fluke Infection

Liver-Fluke Infection

Infection with Opisthorchis viverrini or Clonorchis sinensis is associated with cholangiocarcinoma in areas where these parasites are endemic.
Chronic Liver Disease

Chronic Liver Disease

Cirrhosis, hepatitis B, and hepatitis C are associated particularly with intrahepatic cholangiocarcinoma.
Inflammatory Bowel Disease

Inflammatory Bowel Disease

Ulcerative colitis and Crohn's disease increase risk mainly when associated with primary sclerosing cholangitis.
Increasing Age

Increasing Age

Cholangiocarcinoma occurs more frequently in older adults, although it can develop at any age.
Diabetes, Obesity, and Metabolic Liver Disease

Diabetes, Obesity, and Metabolic Liver Disease

These conditions may increase the risk of intrahepatic cholangiocarcinoma.
Tobacco and Alcohol Use

Tobacco and Alcohol Use

Smoking and prolonged heavy alcohol consumption may contribute to risk.
Previous Exposure to Thorotrast

Previous Exposure to Thorotrast

This older radiological contrast agent is no longer used but was associated with bile-duct and liver cancers
Certain Inherited Conditions

Certain Inherited Conditions

Lynch syndrome, cystic fibrosis, biliary papillomatosis, and some other rare conditions may increase risk.
Most patients do not have a clearly identifiable risk factor. Having a risk factor does not mean that cholangiocarcinoma will develop.

Cholangiocarcinoma Signs and Symptoms

Symptoms depend on whether the tumour blocks a major bile duct or grows within the liver.
Possible signs and symptoms include:

Yellowing of the skin or eyes

Dark urine

Pale or clay-coloured stools

Generalised itching

Persistent pain in the upper-right abdomen

Central or upper abdominal discomfort

Unexplained weight loss

Unexplained weight loss

Feeling full after eating a small amount

Persistent fatigue or weakness

Nausea or vomiting

Fever or chills

Recurrent bile-duct infection

Abdominal swelling

A lump or feeling of fullness below the ribs

Back or shoulder pain

Increasing liver-function abnormalities

Night sweats or general deterioration in advanced disease

Intrahepatic cholangiocarcinoma may grow considerably before causing jaundice because it does not always block a major bile duct. Jaundice with fever, chills, abdominal pain, confusion, or low blood pressure may indicate acute cholangitis and requires urgent medical attention.

How Cholangiocarcinoma Is Diagnosed

Diagnosis begins with a review of symptoms, previous bile-duct or liver disease, inflammatory bowel disease, infection risk, medications, previous procedures, and family history. The doctor examines the abdomen and looks for jaundice, itching-related skin changes, abdominal fluid, weight loss, or enlarged lymph nodes.

Imaging determines where the tumour began, whether bile flow is obstructed, and whether the cancer appears removable. Tissue confirmation is often required, particularly before systemic treatment, but the biopsy approach must be planned carefully.

• •

Ultrasound

Abdominal ultrasound may be the first imaging test when jaundice or abnormal liver tests are present. It can identify:

  • Widened bile ducts

  • A liver mass

  • Gallstones

  • Gallbladder abnormalities

  • Abdominal fluid

Ultrasound may not show the full extent of a bile-duct tumour, so CT or MRI is usually required.

Multiphase CT Scan

Contrast-enhanced CT of the chest, abdomen, and pelvis helps assess:

  • Tumour size and location

  • Involvement of the liver and major blood vessels

  • Bile-duct obstruction

  • Regional lymph nodes

  • The expected amount of liver remaining after surgery

  • Spread to the lungs, peritoneum, or other organs

CT also helps determine whether surgery or image-guided biopsy is technically feasible.

MRI and MRCP

MRI provides detailed images of the liver, bile ducts, blood vessels, and surrounding tissues. Magnetic resonance cholangiopancreatography uses MRI sequences to map the bile ducts without inserting an instrument into them.

MRI with MRCP is particularly useful for perihilar cholangiocarcinoma because it can show:

  • The length and extent of bile-duct involvement

  • Whether one or both sides of the liver are affected

  • Blood-vessel involvement

  • Liver shrinkage or enlargement caused by obstruction

  • Additional liver lesions

Endoscopic Ultrasound

Endoscopic ultrasound uses an ultrasound probe passed through the mouth into the stomach or small intestine. It can assess distal bile-duct tumours, the pancreas, and nearby lymph nodes. Fine-needle aspiration or core biopsy of suspicious lymph nodes or a distal tumour may be performed when clinically appropriate.

ERCP

Endoscopic retrograde cholangiopancreatography involves passing an endoscope to the opening of the bile duct in the small intestine and injecting contrast into the ducts.

ERCP may be used to:

  • Define a narrowing

  • Collect brushings or biopsy samples

  • Drain an obstructed bile duct

  • Place a plastic or metal stent

  • Treat cholangitis

It is used mainly when tissue collection or drainage is required rather than solely for diagnostic imaging.

Percutaneous Transhepatic Cholangiography

During this procedure, a needle and catheter are passed through the skin and liver into an obstructed bile duct. It may be used when ERCP is unsuccessful or unsuitable, particularly for high perihilar obstructions. Tissue samples may be collected, and a drain or stent may be placed.

PET-CT

PET-CT may help identify involved lymph nodes or distant metastases that are not clear on conventional imaging. It is used selectively and does not replace high-quality CT or MRI for assessing local bile-duct anatomy.

Staging Laparoscopy

Laparoscopy may be considered before major surgery for selected higher-risk tumours. It can identify small deposits on the abdominal lining or liver surface that were not visible on scans.

Bile-Duct Brushings

During ERCP, a small brush is passed across the narrowed bile duct to collect cells. Brush cytology can confirm cancer, but a negative result does not exclude it because these tumours can be difficult to sample.

Intraductal Biopsy

Small forceps may be passed into the bile duct during ERCP to collect tissue. Using biopsy with brush cytology can improve the likelihood of diagnosis.

Cholangioscopy-Guided Biopsy

Cholangioscopy places a very small camera directly inside the bile duct. It allows visual assessment of the narrowing and targeted biopsy of suspicious tissue.

Image-Guided Core Needle Biopsy

A liver mass may be sampled through the skin under ultrasound or CT guidance. This is commonly considered for intrahepatic cholangiocarcinoma when tissue confirmation is needed.

Lymph-Node Biopsy

Suspicious distant or regional lymph nodes may be sampled using endoscopic ultrasound or percutaneous image guidance when the result could alter treatment.

Biopsy Planning for Perihilar Tumours

A needle should not be passed through a potentially transplantable perihilar tumour without discussion with the specialist hepatobiliary and transplant team. Transperitoneal sampling may spread tumour cells along the needle pathway and can affect eligibility for certain transplant protocols.

In a clearly resectable tumour with characteristic imaging, surgery may occasionally proceed without preoperative tissue confirmation. The decision is made by the multidisciplinary team.

Laboratory

Blood, bile-duct samples, and tumour tissue help establish the diagnosis, assess organ function, and guide treatment. Evaluation may include:

  • Histopathology: Confirms adenocarcinoma or identifies another tumour such as hepatocellular carcinoma, pancreatic cancer, gallbladder cancer, or metastasis.

  • Tumour differentiation: Assesses how closely the cancer cells resemble normal bile-duct cells.

  • Immunohistochemistry: Helps support a biliary origin and exclude cancer arising in another organ.

  • Margin assessment: Determines whether cancer reaches the edge of a surgically removed bile duct, liver, pancreas, or other tissue.

  • Lymph-node assessment: Records the number of nodes examined and the number containing cancer.

  • Lymphovascular and perineural invasion: Identifies cancer within vessels or around nerves and provides prognostic information.

  • CA 19-9: May be elevated in cholangiocarcinoma and can support monitoring, but it can also rise because of bile-duct obstruction or infection.

  • CEA: May be elevated in some patients but is not specific enough to diagnose the disease.

  • Liver-function tests: Bilirubin, alkaline phosphatase, gamma-glutamyl transferase, aminotransferases, and albumin help assess obstruction and liver function.

  • Complete blood count: May identify anaemia, infection, or low platelets.

  • Kidney function, electrolytes, and clotting tests: Help assess treatment suitability and the effects of jaundice or infection.

  • Mismatch-repair and microsatellite-instability testing: May identify patients who could benefit from immunotherapy and occasionally suggest an inherited cancer predisposition.

  • FGFR2 testing: Fusions or rearrangements are found mainly in a subset of intrahepatic cholangiocarcinomas and may guide targeted treatment.

  • IDH1 testing: An IDH1 alteration may identify selected advanced intrahepatic cancers suitable for targeted therapy.

  • BRAF testing: A BRAF V600E alteration may guide combined targeted treatment in selected advanced cancers.

  • HER2 testing: Amplification or overexpression may be relevant particularly in some extrahepatic bile-duct cancers.

  • Broader molecular profiling: May identify rare alterations involving NTRK, RET, or other genes that could influence treatment or clinical-trial eligibility.

CA 19-9 cannot diagnose cholangiocarcinoma by itself. It should preferably be interpreted after bile-duct infection and significant obstruction have been addressed. Some individuals do not produce CA 19-9 because of their inherited blood-group biology.

Staging of Cholangiocarcinoma

Intrahepatic, perihilar, and distal cholangiocarcinomas have separate TNM staging systems because they arise in different anatomical locations.

Cholangiocarcinoma may be broadly described as:

  • Stage I: The cancer remains localised to the bile duct or liver without lymph-node or distant spread.

  • Stage II: The tumour has grown further into nearby tissue, involves blood vessels, or, for intrahepatic disease, may include multiple tumours.

  • Stage III: The cancer has reached major local structures or regional lymph nodes.

  • Stage IV: The cancer has spread to distant lymph nodes, the peritoneum, lungs, bones, or other organs.

Bile Duct Cancer Bile Duct Cancer

How Cholangiocarcinoma Is Treated

• • •

Liver Resection

Intrahepatic cholangiocarcinoma is usually treated by removing the affected section of the liver together with an adequate margin and regional lymph nodes. The extent of surgery depends on tumour size, number, location, blood-vessel involvement, and the amount and function of liver that will remain.

Perihilar Bile-Duct Resection

Surgery for perihilar cholangiocarcinoma usually removes:

  • The affected extrahepatic bile ducts

  • Part of the liver

  • The caudate lobe

  • Regional lymph nodes

  • Involved blood vessels when reconstruction is feasible and appropriate

The remaining bile duct is connected to the small intestine to restore bile drainage.

Pancreaticoduodenectomy

Distal cholangiocarcinoma is commonly treated with pancreaticoduodenectomy, also called the Whipple procedure. The operation removes the distal bile duct, pancreatic head, duodenum, gallbladder, and nearby lymph nodes. The digestive and biliary systems are then reconstructed.

Portal-Vein Embolisation

When the portion of liver expected to remain after surgery is too small, portal-vein embolisation may be performed before the operation. It redirects blood flow to the future liver remnant and encourages it to grow.

Lymph Node Dissection

Regional lymph nodes are removed during curative surgery because nodal status provides important staging and prognostic information.

Liver Transplantation

Liver transplantation may be considered for highly selected patients with unresectable perihilar cholangiocarcinoma who meet strict criteria and complete a specialised neoadjuvant treatment protocol. Transplantation is not standard for most cholangiocarcinomas. Its use for selected intrahepatic cancers remains limited to specialised protocols and clinical investigation.

Surgery for Recurrent or Metastatic Disease

Repeat resection may be considered when recurrence is limited and complete removal appears possible. Surgery for metastatic disease is reserved for highly selected cases after multidisciplinary review.

Adjuvant Chemotherapy

Chemotherapy may be recommended after complete surgical removal to reduce the risk of recurrence. Capecitabine is commonly used as adjuvant treatment for eligible patients with resected biliary-tract cancer. Further treatment may be considered when margins are involved or lymph nodes contain cancer.

Chemotherapy for Advanced Disease

Gemcitabine combined with cisplatin is a commonly used chemotherapy foundation for unresectable or metastatic cholangiocarcinoma. Other combinations may be used according to kidney function, hearing, nerve function, previous treatment, and general health.

Immunotherapy

An immune-checkpoint inhibitor may be combined with gemcitabine and cisplatin for suitable patients with advanced biliary-tract cancer. Immunotherapy may also be used for selected tumours with mismatch-repair deficiency, high microsatellite instability, or another relevant biomarker. Immune-related effects can involve the liver, bowel, lungs, skin, thyroid, adrenal glands, or other organs and require prompt assessment.

FGFR-Targeted Therapy

FGFR inhibitors may be used for selected advanced intrahepatic cholangiocarcinomas with an eligible FGFR2 fusion or rearrangement, particularly after previous systemic treatment.

IDH1-Targeted Therapy

An IDH1 inhibitor may be considered for selected previously treated advanced cholangiocarcinomas with an IDH1 alteration.

BRAF and MEK-Targeted Therapy

Combined BRAF and MEK inhibition may be used for selected advanced cancers containing a BRAF V600E alteration.

HER2-Targeted Therapy

HER2-directed treatment may be considered for selected advanced HER2-positive biliary-tract cancers. The evidence and available medicines vary according to tumour location, previous treatment, and regulatory approval.

External Beam Radiation Therapy

Radiation therapy may be used:

  • After surgery when margins are involved or other high-risk features are present

  • With chemotherapy for selected unresectable local disease

  • To control a local recurrence

  • To relieve pain, bleeding, obstruction, or other symptoms

  • To treat metastatic disease in the bones, brain, or other organs

Intensity-Modulated Radiation Therapy

Intensity-modulated radiation therapy shapes the treatment dose around the tumour and regional lymph nodes while reducing exposure to the remaining liver, kidneys, bowel, stomach, and spinal cord.

Stereotactic Body Radiation Therapy

Stereotactic body radiation therapy delivers a highly focused dose over a limited number of sessions. It may be considered for selected intrahepatic tumours, limited recurrences, or metastatic deposits. Suitability depends on tumour size, location, liver function, nearby bile ducts and bowel, and previous treatment.

Proton Therapy

Proton therapy may be considered when reducing radiation exposure to the healthy liver, kidneys, stomach, bowel, or other organs offers a meaningful advantage. Its role depends on tumour anatomy, liver reserve, previous treatment, and comparison with an advanced photon-radiation plan.

Brachytherapy

Intraluminal brachytherapy places a radiation source temporarily within the bile duct. It may be considered in selected unresectable tumours to improve local control or maintain bile-duct openness.

Radiofrequency or Microwave Ablation

Thermal ablation may be used for selected small intrahepatic cholangiocarcinomas when surgery is unsuitable or for limited recurrent disease.

Transarterial Treatment

Chemoembolisation or radioembolisation may be considered for selected liver-dominant intrahepatic cholangiocarcinoma. These treatments are not appropriate for every patient and depend on tumour distribution, liver function, blood-vessel anatomy, and disease outside the liver.

Bile Duct Cancer
Prognosis for Cholangiocarcinoma

The outlook for cholangiocarcinoma depends mainly on its location, stage, lymph-node involvement, and whether the tumour can be completely removed.

Factors that may influence prognosis include:
Intrahepatic, perihilar, or distal location
Tumour size and number
Blood-vessel involvement
Regional lymph-node involvement
Spread to the peritoneum or distant organs
Surgical-margin status
Tumour grade
Lymphovascular and perineural invasion
Liver function and presence of chronic liver disease
Response to chemotherapy, immunotherapy, radiation, or targeted treatment
Molecular features
General health and nutritional status

Surgery offers the main possibility of cure, but recurrence can occur even after complete removal. Advanced cholangiocarcinoma is generally not considered curable, although modern chemotherapy, immunotherapy, targeted medicines, radiation, and biliary procedures can control the disease and relieve symptoms.

Why Choose ACC for Cholangiocarcinoma Treatment

Multidisciplinary care involving hepatobiliary and pancreatic surgery, liver transplantation, medical oncology, radiation oncology, gastroenterology, interventional radiology, pathology, imaging, nutrition, and supportive care

Multiphase CT, MRI with MRCP, endoscopic ultrasound, ERCP, PET-CT, and image-guided biopsy

Specialist assessment of intrahepatic, perihilar, and distal bile-duct cancers

Complex liver, bile-duct, vascular, and pancreatic surgery

Portal-vein embolisation and future-liver-remnant assessment before major resection

Liver-transplant assessment for appropriately selected perihilar tumours

Endoscopic and percutaneous biliary drainage

Adjuvant chemotherapy and combined chemo-immunotherapy for eligible patients

Comprehensive molecular profiling and targeted treatment assessment

Stereotactic radiation and proton therapy for selected tumours

Ablation, chemoembolisation, and radioembolisation for appropriate liver-dominant disease

Structured surveillance, nutritional care, stent management, and supportive or palliative care
Frequently Asked Questions
01 Are cholangiocarcinoma and bile-duct cancer the same?
icon icon
Cholangiocarcinoma is the most common type of bile-duct cancer. It may develop inside the liver, at the liver hilum, or in the lower bile duct near the pancreas.
02 Is intrahepatic cholangiocarcinoma a liver cancer?
icon icon
It begins within the liver but arises from bile-duct cells rather than hepatocytes. It is therefore biologically and therapeutically different from hepatocellular carcinoma.
03 Does jaundice always mean bile-duct cancer?
icon icon
No. Gallstones, hepatitis, pancreatic disease, medicines, and other conditions can cause jaundice. New jaundice nevertheless requires prompt medical evaluation.
04 Can cholangiocarcinoma occur without jaundice?
icon icon
Yes. Intrahepatic tumours often do not cause jaundice until advanced because they may not obstruct a major bile duct.
05 Is a biopsy always required?
icon icon
Not always. A clearly resectable tumour with characteristic imaging may occasionally proceed to surgery without biopsy. Tissue confirmation is generally required before systemic treatment or when the diagnosis is uncertain.
06 Why must biopsy of a perihilar tumour be carefully planned?
icon icon
Passing a needle through a potentially transplantable perihilar tumour may spread cancer cells along the needle pathway and affect transplant eligibility. Sampling should be coordinated with the specialist team.
07 What is the purpose of a bile-duct stent?
icon icon
A stent opens a blocked bile duct so that bile can drain. It can relieve jaundice and itching, treat or prevent infection, and improve liver function before further treatment.
08 Can cholangiocarcinoma be cured?
icon icon
Surgery can provide a possibility of cure when the cancer can be completely removed. Selected perihilar tumours may be treated using a specialised transplant protocol. Advanced disease is usually controlled rather than cured.
09 Is liver transplantation used for bile-duct cancer?
icon icon
It may be considered for highly selected patients with unresectable perihilar cholangiocarcinoma who meet strict criteria and complete specialised pre-transplant treatment. It is not suitable for most patients.
10 Why is molecular testing important?
icon icon
Advanced cholangiocarcinoma can contain alterations involving FGFR2, IDH1, BRAF, HER2, NTRK, or other genes. Identifying them may create a targeted-treatment option.
11 Can cholangiocarcinoma return after surgery?
icon icon
Yes. It may return near the original site, elsewhere in the liver, in lymph nodes, on the abdominal lining, or in distant organs. Structured surveillance is therefore important.
12 Where does cholangiocarcinoma commonly spread?
icon icon
It may spread to regional or distant lymph nodes, the liver, peritoneum, lungs, bones, adrenal glands, or other organs.
image image
Book an Appointment
Please Enter Your Name
Please Enter Your Mobile Number
Please Enter OTP